A8D Stock Overview
A clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
AB Science S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.37 |
| 52 Week High | €2.56 |
| 52 Week Low | €0.73 |
| Beta | 1.46 |
| 1 Month Change | -11.71% |
| 3 Month Change | 86.41% |
| 1 Year Change | -39.82% |
| 3 Year Change | -84.32% |
| 5 Year Change | -76.10% |
| Change since IPO | -89.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| A8D | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -3.2% | -1.6% |
| 1Y | -39.8% | -14.8% | 13.8% |
Return vs Industry: A8D underperformed the German Pharmaceuticals industry which returned -14.7% over the past year.
Return vs Market: A8D underperformed the German Market which returned 12% over the past year.
Price Volatility
| A8D volatility | |
|---|---|
| A8D Average Weekly Movement | 17.5% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: A8D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: A8D's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 40 | Alain Moussy | www.ab-science.com |
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia.
AB Science S.A. Fundamentals Summary
| A8D fundamental statistics | |
|---|---|
| Market cap | €90.96m |
| Earnings (TTM) | -€6.04m |
| Revenue (TTM) | €1.08m |
84.1x
P/S Ratio-15.1x
P/E RatioIs A8D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A8D income statement (TTM) | |
|---|---|
| Revenue | €1.08m |
| Cost of Revenue | €257.00k |
| Gross Profit | €825.00k |
| Other Expenses | €6.87m |
| Earnings | -€6.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 76.25% |
| Net Profit Margin | -558.50% |
| Debt/Equity Ratio | -73.6% |
How did A8D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/12 19:10 |
| End of Day Share Price | 2025/03/12 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AB Science S.A. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark van der Geest | ABN AMRO Bank N.V. |
| Michael Ryskin | BofA Global Research |
| Jean-Pierre Loza | In Extenso Financement & Marché |